CTLA4 and neoplasm: Syngeneic tumor models have also been applied to the investigation of the anti-tumor activity of ICIs, including anti-programmed death (PD)-1/anti-PD-ligand 1 (L1) antibodies [71,72] and anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) [46].